|
Registered number:
For the year ended
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Apollo Scientific Ltd
Company Information
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Apollo Scientific Ltd
Contents
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Apollo Scientific Ltd
Strategic report
For the year ended 31 December 2024
The directors present the strategic report for the year ended 31 December 2024.
The results for the period were considered disappointing by the directors with an operating loss of £759k recorded, however the overall financial position remains strong with cash reserves of £4.0m.
Turnover decreased by £1.8m to £9.5m (16%) when compared to the prior year. This was largely attributed to continuing poor market conditions, as a result of continuing inflationary pressures impacting worldwide economies particularly within the local UK market, resulting in a large double digit decrease within the bulk side of the business, especially within the pharmaceutical sector. The company are looking to expand commercial activities within the broader industrial chemicals sector to reduce reliance on pharmaceutical business. Catalogue business also showed a single digit decline on the prior year due to both decreased spending budgets at key clients and increasing competition from overseas competitors. The company are responding to this through continuing adaption of its product range and placing more focus on moving into new product lines with less competition and offering a more complete laboratory product and service solution to its customer base. The directors were pleased to report that, despite ongoing issues as a result of Brexit, the EU market remained consistent with prior year’s sales and the company hope to further capitalise on this through the now established subsidiary company Apollo Scientific GmbH (Germany) and development of EU stock location in 2025. Gross profit % increased slightly by 2% to 35.6% as a result of a higher proportion of sales coming from higher margin catalogue business. Overheads reduced by £504k (11%) compared to previous year, largely due to a reduction in staff numbers most notably within production and some administrative areas. The directors and executive management team expect to see an improvement in turnover and return to profitability in the near future through expanding business development resource and increasing profile in non-pharmaceutical sectors to develop more stable demand bulk projects. The company remains committed to achieving long term stability through achieving higher throughput within the catalogue business and considerably reducing the current cost to process an order by continuing to prioritise investment within IT and automation projects to improve efficiency and reduce labour demands in this area. Investment within automated carousel stocking machines have assisted in improving warehouse efficiency and reduce warehouse footprint which has enabled the company to consolidate all operations onto one site from the beginning of 2025. This is anticipated to help improve communication and further streamline processes and develop efficiencies to ultimately drive profitability within the catalogue business.
Page 1
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Apollo Scientific Ltd
Strategic report (continued)
For the year ended 31 December 2024
The company trades in overseas markets. Both sales and purchases are made in foreign currencies therefore a natural hedge exists to an extent. Prices are constantly monitored and where unfavourable exchange rate movements are expected, are altered accordingly where possible.
Credit risk is managed by standard procedures including the use of credit rating agencies when deciding upon credit terms and the ongoing monitoring of accounts. Liquidity risk is managed by keeping sufficient cash deposits in order to meet liabilities as they fall due. The company sells into a range of different markets across the international stage and is therefore exposed to risks associated with declining economies within these markets. This is offset to some extent by trading to a number of different countries and industrial sectors however the company are working to reduce reliance on the pharmaceutical sector which had accounted for a large proportion of bulk sales within recent years. Operating within the chemical industry, the company is subject to a number of laws and regulations and remain at risk to changing legislation which could impact ability to trade in certain product lines or markets. This can impact both product sales and overheads through increasing cost of compliance.
A summary of the financial key performance indicators for the past five years is as follows:
This report was approved by the board and signed on its behalf.
Page 2
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Apollo Scientific Ltd
Directors' report
For the year ended 31 December 2024
The directors present their report and the financial statements for the year ended 31 December 2024.
The directors are responsible for preparing the Strategic report, the Directors' report and the financial statements in accordance with applicable law and regulations.
In preparing these financial statements, the directors are required to:
∙select suitable accounting policies for the company's financial statements and then apply them consistently;
∙make judgements and accounting estimates that are reasonable and prudent;
∙state whether applicable UK Accounting Standards have been followed, subject to any material departures disclosed and explained in the financial statements;
∙prepare the financial statements on the going concern basis unless it is inappropriate to presume that the company will continue in business.
The directors are responsible for keeping adequate accounting records that are sufficient to show and explain the company's transactions and disclose with reasonable accuracy at any time the financial position of the company and to enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.
The loss for the year, after taxation, amounted to £412,954 (2023 -loss £788,601).
Dividends declared in the year amount to £Nil (2023- £Nil).
The directors who served during the year were:
The company is focusing on building a sustainable long term model for its catalogue business through developing processes to reduce the cost to service an order by investing in technology to introduce more automation into processes and continues to explore ways to create streamlined and efficient working methods, alongside improving access for international markets through establishment of overseas subsidiaries and stocking locations in order to increase market share. The company is working on ways to improve access to inventory through exploring strategic partnerships with third parties to assist with this as well as developing higher value product lines with less competition.
Page 3
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Apollo Scientific Ltd
Directors' report (continued)
For the year ended 31 December 2024
The company continues to invest in research and development to increase in-house production capabilities in order to enable fulfilment of more client custom projects and increase the number of novel higher value products being brought to market.
Accreditations The company is committed to ensuring it conducts all its activities in full compliance with all laws and regulations whilst maintaining a high ethical and social standing with great emphasis placed on environmental, social and governance (ESG) principles. The company produces an annual CSR report and continues to lead the way within its sector being one of few to hold the EcoVadis Platinum award for corporate sustainability, a medal held since 2020, placing it within the top 1% of companies assessed within the sector. The company remains signatories to the UN Global Compact, reporting an annual Communication of Progress, and has maintained its ISO 9001:2015 and 12001:2015 accreditations along with holding Known Consignor and Authorised Economic Operator status.
The principal risks and uncertainties including reference to financial instruments are included in the strategic report.
There have been no significant events affecting the company since the year end.
The auditors, Hurst Accountants Limited, will be proposed for reappointment in accordance with section 485 of the Companies Act 2006.
This report was approved by the board and signed on its behalf.
Page 4
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Apollo Scientific Ltd
Independent auditors' report to the members of Apollo Scientific Ltd
We have audited the financial statements of Apollo Scientific Ltd (the 'company') for the year ended 31 December 2024, which comprise the Statement of comprehensive income, the Balance sheet, the Statement of cash flows, the Statement of changes in equity and the related notes, including a summary of significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including Financial Reporting Standard 102 ‘The Financial Reporting Standard applicable in the UK and Republic of Ireland' (United Kingdom Generally Accepted Accounting Practice).
We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditors' responsibilities for the audit of the financial statements section of our report. We are independent of the company in accordance with the ethical requirements that are relevant to our audit of the financial statements in the United Kingdom, including the Financial Reporting Council's Ethical Standard and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.
In auditing the financial statements, we have concluded that the directors' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.
Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the company's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.
Our responsibilities and the responsibilities of the directors with respect to going concern are described in the relevant sections of this report.
The other information comprises the information included in the annual report other than the financial statements and our Auditors' report thereon. The directors are responsible for the other information contained within the annual report. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon. Our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the course of the audit, or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether this gives rise to a material misstatement in the financial statements themselves. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact.
We have nothing to report in this regard.
Page 5
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Apollo Scientific Ltd
Independent auditors' report to the members of Apollo Scientific Ltd (continued)
In our opinion, based on the work undertaken in the course of the audit:
∙the information given in the Strategic report and the Directors' report for the financial year for which the financial statements are prepared is consistent with the financial statements; and
∙the Strategic report and the Directors' report have been prepared in accordance with applicable legal requirements.
In the light of the knowledge and understanding of the company and its environment obtained in the course of the audit, we have not identified material misstatements in the Strategic report or the Directors' report.
Page 6
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Apollo Scientific Ltd
Independent auditors' report to the members of Apollo Scientific Ltd (continued)
Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an Auditors' report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.
Irregularities, including fraud, are instances of non-compliance with laws and regulations. We design procedures in line with our responsibilities, outlined above, to detect material misstatements in respect of irregularities, including fraud. The extent to which our procedures are capable of detecting irregularities, including fraud is detailed below:
We identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, and then design and perform audit procedures responsive to those risks, including obtaining audit evidence that is sufficient and appropriate to provide a basis for our opinion.
Identifying and assessing potential risks related to irregularities
In identifying and assessing the risks of material misstatement in respect of irregularities, including fraud and non-compliance with laws and regulations, we considered the following:
∙The nature of the industry and sector, control environment and business performance including key drivers for directors' remuneration, bonus levels and performance targets.
∙Enquiring of local management and parent company management, including obtaining and reviewing supporting documentation, concerning the company's policies and procedures relating to:
°Identifying, evaluating and complying with laws and regulations and whether they were aware of any instances of non-compliance;
°Detecting and responding to the risks of fraud and whether they have knowledge of any actual, suspected of alleged fraud;
∙The internal controls established to mitigate risks related to fraud or non-compliance with laws and regulations.
∙Discussing among the engagement team regarding how and where fraud might occur in the financial statements and any potential indicators of fraud;
∙Obtaining an understanding of the legal and regulatory frameworks that the Company operates in, focusing on those laws and regulations that had a direct effect on the financial statements, such as the Companies Act 2006, pensions and tax legislation, or that had a fundamental effect on the operations of the Company, including General Data Protection requirements, Anti-bribery and Health & Safety.
Audit response to risks identified
Our procedures to respond to risk identified included the following:
∙Reviewing the financial statement disclosures and testing to supporting documentation to assess compliance with provisions of relevant laws and regulations described as having a direct effect on the financial statements;
∙Discussions with management, including consideration of known or suspected instances of non-compliance with laws and regulations and fraud;
∙Evaluation of management’s controls designed to prevent and detect irregularities;
∙Enquiring of management concerning actual and potential litigation and claims;
∙Performing analytical procedures to identify any unusual or unexpected relationships that may indicate risks of material misstatement due to fraud;
∙Reading minutes of meetings of those charged with governance and correspondence with regulators.
Page 7
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Apollo Scientific Ltd
Independent auditors' report to the members of Apollo Scientific Ltd (continued)
We have also considered the risks noted above in addressing the risk of fraud through management override of controls:
∙Testing the appropriateness of journal entries and other adjustments; we have used data analytics software to runs tests designed to identify accounting transactions which may pose a heightened risk of material misstatement, whether due to fraud or error.
∙Challenging assumptions made by management in their significant accounting estimates, and assessing whether the judgements made in making accounting estimates are indicative of a potential bias; and
∙Evaluating the business rationale of any significant transactions that are unusual or outside the normal course of business.
We also communicated relevant identified laws and regulations and potential fraud risks to all engagement team members and remained alert to any indications of fraud or non-compliance with laws and regulations throughout the audit.
There are inherent limitations in the audit procedures described above, and the further removed non-compliance with laws and regulations is from the events and transactions reflected in the financial statements, the less likely we would become aware of it. Also, the risk of not detecting a material misstatement due to fraud is higher than the risk of not detecting one resulting from error, as fraud may involve deliberate concealment by, for example, forgery or intentional misrepresentations, or through collusion.
A further description of our responsibilities for the audit of the financial statements is located on the Financial Reporting Council's website at: www.frc.org.uk/auditorsresponsibilities. This description forms part of our Auditors' report.
This report is made solely to the company's members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006. Our audit work has been undertaken so that we might state to the company's members those matters we are required to state to them in an Auditors' report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the company and the company's members, as a body, for our audit work, for this report, or for the opinions we have formed.
for and on behalf of
Chartered Accountants
Statutory Auditors
3 Stockport Exchange
Stockport
Cheshire
SK1 3GG
Page 8
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Apollo Scientific Ltd
Statement of comprehensive income
For the year ended 31 December 2024
Page 9
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Apollo Scientific Ltd
Registered number: 02856632
Balance sheet
As at
The financial statements were approved and authorised for issue by the board and were signed on its behalf by:
The notes on pages 14 to 28 form part of these financial statements.
Page 10
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Apollo Scientific Ltd
Statement of changes in equity
For the year ended 31 December 2024
Page 11
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Apollo Scientific Ltd
Statement of cash flows
For the year ended 31 December 2024
Page 12
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Apollo Scientific Ltd
Analysis of Net Debt
For the year ended 31 December 2024
Page 13
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Apollo Scientific Ltd
Notes to the financial statements
For the year ended 31 December 2024
Apollo Scientific Limited is a private company limited by share capital incorporated in England, registered number 02856632. The address of the registered office and principal place of business is Unit 3&4 Parkway, Denton, Manchester, England, M34 3SG.
The nature of the company's operation and its principal activity is that of the supply of chemicals and other related products.
2.Accounting policies
The financial statements have been prepared under the historical cost convention unless otherwise specified within these accounting policies and in accordance with Financial Reporting Standard 102, the Financial Reporting Standard applicable in the UK and the Republic of Ireland and the Companies Act 2006.
The preparation of financial statements in compliance with FRS 102 requires the use of certain critical accounting estimates. It also requires management to exercise judgement in applying the company's accounting policies (see note 3).
The following principal accounting policies have been applied:
The directors have prepared the financial statements on a going concern basis which assumes the company will have sufficient reserves to meet liabilities as they fall due.
During the year ended 31 December 2024, the company reported losses of £412,954 (2023: £788,601) and net assets of £11,852,305 (2023: £12,265,259) and cash reserves of £4,006,429 (2023: £5,190,074) at 31 December 2024. The directors have prepared forecasts for the next financial year which show a growth in sales and a significantly smaller loss is expected. The Senior Management Team remain confident that 2025 budgets will be met considering the strong backorders position as at end January 2025 and given the significant cash reserves and net asset position, the directors have no concerns over meeting liabilities as they fall due
Page 14
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Apollo Scientific Ltd
Notes to the financial statements
For the year ended 31 December 2024
2.Accounting policies (continued)
The company adds to the carrying amount of an item of fixed assets the cost of replacing part of such an item when that cost is incurred, if the replacement part is expected to provide incremental future benefits to the company. The carrying amount of the replaced part is derecognised. Repairs and maintenance are charged to profit or loss during the period in which they are incurred.
Depreciation is charged so as to allocate the cost of assets less their residual value over their estimated useful lives, using the straight-line method.
Depreciation is provided on the following basis:
The assets' residual values, useful lives and depreciation methods are reviewed, and adjusted prospectively if appropriate, or if there is an indication of a significant change since the last reporting date.
Gains and losses on disposals are determined by comparing the proceeds with the carrying amount and are recognised in profit or loss.
All intangible assets are considered to have a finite useful life. If a reliable estimate of the useful life cannot be made, the useful life shall not exceed ten years.
The estimated useful lives range as follows:
Page 15
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Apollo Scientific Ltd
Notes to the financial statements
For the year ended 31 December 2024
2.Accounting policies (continued)
Functional and presentation currency
Transactions and balances
The company only enters into basic financial instruments transactions that result in the recognition of financial assets and liabilities like trade and other accounts receivable.
Debt instruments that are payable or receivable within one year, typically trade debtors and creditors, are measured, initially and subsequently, at the undiscounted amount of the cash or other consideration expected to be paid or received. Financial assets that are measured at cost and amortised cost are assessed at the end of each reporting period for objective evidence of impairment. If objective evidence of impairment is found, an impairment loss is recognised in the Statement of comprehensive income. For financial assets measured at amortised cost, the impairment loss is measured as the difference between an asset's carrying amount and the present value of estimated cash flows discounted at the asset's original effective interest rate. If a financial asset has a variable interest rate, the discount rate for measuring any impairment loss is the current effective interest rate determined under the contract. Financial assets and liabilities are offset and the net amount reported in the Balance sheet when there is an enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.
Page 16
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Apollo Scientific Ltd
Notes to the financial statements
For the year ended 31 December 2024
2.Accounting policies (continued)
Research and development costs are written off in the period they are incurred.
Page 17
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Apollo Scientific Ltd
Notes to the financial statements
For the year ended 31 December 2024
2.Accounting policies (continued)
Provisions are measured as the best estimate of the amount required to settle the obligation, taking into account the related risks and uncertainties.
Page 18
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Apollo Scientific Ltd
Notes to the financial statements
For the year ended 31 December 2024
Provision for impairment loss on trade receivables The management of the company exercises significant judgement in providing for impairment loss on trade receivables. Should these estimates vary, the profit or loss and balance sheet of the following years could be significantly impacted. The carrying value of trade receivables was £1,489,451 (2023 - £1,734,104). Provision for obsolete and slow moving stocks The company reviews its stocks to assess loss on account of obsolescence on a regular basis. In determining whether provision for obsolescence should be recorded in profit or loss, the company makes judgements as to whether there is any observable data indicating that there is any future saleability of the product and the estimated net realisable value for such product. Accordingly, provision for impairment is made where the net realisable value is less than the cost based on best estimates by the management. The provision for obsolescence of stock is based on the ageing and historical sales pattern. The carrying value of stocks was £5,414,334 (2023 - £5,770,416).
Analysis of turnover by country of destination:
Page 19
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Apollo Scientific Ltd
Notes to the financial statements
For the year ended 31 December 2024
Page 20
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Apollo Scientific Ltd
Notes to the financial statements
For the year ended 31 December 2024
Page 21
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Apollo Scientific Ltd
Notes to the financial statements
For the year ended 31 December 2024
Page 22
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Apollo Scientific Ltd
Notes to the financial statements
For the year ended 31 December 2024
10.Taxation (continued)
There is an unrecognised deferred tax asset of £69,306 relating to unutilised losses.
Page 23
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Apollo Scientific Ltd
Notes to the financial statements
For the year ended 31 December 2024
Page 24
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Apollo Scientific Ltd
Notes to the financial statements
For the year ended 31 December 2024
Page 25
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Apollo Scientific Ltd
Notes to the financial statements
For the year ended 31 December 2024
Page 26
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Apollo Scientific Ltd
Notes to the financial statements
For the year ended 31 December 2024
18.Deferred taxation (continued)
Profit and loss account
The profit and loss account includes all current and prior period retained profits and losses.
The company operates a defined contribution pension scheme. The scheme and its assets are held by independent managers. The pension charge represents contributions due from the company and amounted to £143,762 (2023 - £172,606). Contributions totalling £828 (2023 - £1,110) were payable to the fund at the balance sheet date and are included in creditors.
Page 27
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Apollo Scientific Ltd
Notes to the financial statements
For the year ended 31 December 2024
The company is a wholly owned subsidiary of Central Glass Co. Ltd, a company incorporated in Japan and is listed on the Tokyo Stock Exchange (First Section) in Japan. Central Glass Co. Ltd holds 100% of the issued share capital in Apollo Scientific Limited.
Page 28
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||